A Cost Per Responder Analysis of Secukinumab Vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatmetn of Psoriatic Arthritis at 48 Weeks from the Irish Payer Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.758
https://www.valueinhealthjournal.com/article/S1098-3015(17)31092-6/fulltext
Title :
A Cost Per Responder Analysis of Secukinumab Vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatmetn of Psoriatic Arthritis at 48 Weeks from the Irish Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31092-6&doi=10.1016/j.jval.2017.08.758
First page :
A532
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
722